For best experience we recommend to activate Javascript in your browser.

Q-VD-OPh (General Caspase Inhibitor)

Name: Q-VD-OPh (General Caspase Inhibitor)
SKU: ABIN2691047
Availability: OutOfStock

BR, InhA (3S)-5-(2,6-Difluorophenoxy)-3-[[(2S)-3-methyl-1-oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate

(4 references)

Catalog No. ABIN2691047

Shipping to: United States

Contact our Customer Service for availability and price in your country. Contact Info

Quick Overview for Q-VD-OPh (General Caspase Inhibitor) (ABIN2691047)

Application

Blocking Reagent (BR), Inhibition Assay (InhA)

Chemical Name

(3S)-5-(2,6-Difluorophenoxy)-3-[[(2S)-3-methyl-1-oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate

Purpose

A pan-caspase inhibitor

Sequence

Quinolyl-Val-Asp-OPh

Characteristics

The caspase family of cysteine proteases plays a key role in apoptosis and inflammation. Q-VD-OPh is a potent, cell-permeable inhibitor of caspase activity. It irreversibly inhibits the activity of a broad range of caspases, including caspases-1, -2, -3, -5, -6, -7, -8, -9, -10, and -12. Deemed a next generation caspase inhibitor, Q-VD-OPh has increased selectivity for the caspases over other cysteine proteases, increased potency, and decreased toxicity compared to the previous generation of caspase inhibitors. Additionally, other pan caspase inhibitors do not inhibit all caspases equally. Q-VD-OPh, in contrast, inhibits the spectrum of caspases more equally and at lower concentrations, thus making it a true broad spectrum caspase inhibitor. Flow cytometric analysis of apoptosis in human T-Cell leukemia. Jurkat cells (ATCC, TIB-152) were preincubated with either 20 μM Q-VD-OPh (left) or no inhibitor for 30 minutes and then either left untreated (right) or treated with 20 μM camptothecin (center) for 5 hours. Following incubation, cells were collected and stained with PE Annexin V (Cat. No. 556421) and 7-AAD (Cat. No. 559925) to identify cells undergoing apoptosis. Flow cytometry was performed on a BD LSRFortessa™ flow cytometry system. The results indicate that in camptothecin treated cells, approximately 37 % of the cells were induced to undergo apoptosis. In both the inhibitor treated and untreated cells, approximately 1 % of cells underwent apoptosis. Thus, the use of the general caspase inhibitor Q-VD-OPh reduced the level of apoptosis to that observed in the untreated control.

Formula

C26H25F2N3O6 · xH2O

Solubility

DMSO
Geldanamycin- FITC
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Geldanamycin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Radicicol
Inh 12772-57-5

Geldanamycin- Biotin
Inh 30562-34-6 (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo[16.3.1] docosa-1(21),4,6,10,18-pentaen-9-yl carbamate

Herbimycin A
Inh 70563-58-5 [(2R,3S,5S,6R,7S,8E,10S,11S,12E,14E)-2,5,6,11-tetramethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

17-GMB-APA-GA
Inh [(3R,5S,6R,7S,10S,11S)-21-[3-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]propylamino]-6-hydroxy-5,11-dimethoxy-3,7,9,15-tetramethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate

TEMPO
Inh 2564-83-2 2,2,6,6-Tetramethylpiperidine 1-oxyl, 2,2,6,6-Tetramethyl-1-piperidinyloxy, free radical, (2,2,6,6-Tetramethyl-1-piperidinyl)oxidanyl, 1,1,5,5-tetramethylpentamethylene nitroxide, 2,2,6,6-Tetramethylpiperidine-1-oxyl

Triacsin C
Inh 76896-80-5 (3E)-1-Oxo-3-[(2E,4E,7E)-2,4,7-undecatrien-1-ylidene]triazane

TPCK
Inh 402-71-1 N-(4-Chloro-3-oxo-1-phenyl-2-butanyl)-4-methylbenzenesulfonamide

Staurosporine
Inh 62996-74-1 (2S,3R,4R,6R)-3-Methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one

Comment

BD Pharmingen™ Q-VD-OPh, General Caspase Inhibitor
The caspase family of cysteine proteases plays a key role in apoptosis and inflammation. Q-VD-OPh is a potent, cell-permeable inhibitor of caspase activity. It irreversibly inhibits the activity of a broad range of caspases, including caspases-1, -2, -3, -5, -6, -7, -8, -9, -10, and -12. Deemed a next generation caspase inhibitor, Q-VD-OPh has increased selectivity for the caspases over other cysteine proteases, increased potency, and decreased toxicity compared to the previous generation of caspase inhibitors. Additionally, other pan caspase inhibitors do not inhibit all caspases equally. Q-VD-OPh, in contrast, inhibits the spectrum of caspases more equally and at lower concentrations, thus making it a true broad spectrum caspase inhibitor.

Restrictions

For Research Use only
Format

Lyophilized

Reconstitution

Reconstitute the Q-VD-OPh inhibitor in DMSO before use. The reconstituted Q-VD-OPh inhibitor may be stored in small aliquots at -20 °C.

Buffer

Lyophilized in dimethyl sulfoxide (DMSO).

Storage

-20 °C

Storage Comment

Avoid multiple freeze-thaws of product. Store the lyophilized Q-VD-OPh inhibitor at -20°C. Reconstitute the Q-VD-OPh inhibitor in DMSO before use. The reconstituted Q-VD-OPh inhibitor may be stored in small aliquots at -20°C.
Kuželová, Grebeňová, Brodská: "Dose-dependent effects of the caspase inhibitor Q-VD-OPh on different apoptosis-related processes." in: Journal of cellular biochemistry, Vol. 112, Issue 11, pp. 3334-42, (2011) (PubMed).

Brown: "Q-VD-OPh, next generation caspase inhibitor." in: Advances in experimental medicine and biology, Vol. 559, pp. 293-300, (2008) (PubMed).

Chauvier, Ankri, Charriaut-Marlangue, Casimir, Jacotot: "Broad-spectrum caspase inhibitors: from myth to reality?" in: Cell death and differentiation, Vol. 14, Issue 2, pp. 387-91, (2007) (PubMed).

Caserta, Smith, Gultice, Reedy, Brown: "Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties." in: Apoptosis : an international journal on programmed cell death, Vol. 8, Issue 4, pp. 345-52, (2003) (PubMed).
Molecular Weight

513 Da